Loading the session
Loading the session
Loading instrument
$70.06
−3.78%DelayedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:27 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: −8.5% (SPY −1.6%, XLV +13.5%). 3 months: −38.9% (SPY −0.4%, XLV +15.5%). 1 year: −12.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: MNPR, SPY and XLV · as of 4 Nov 2026
1.1M shares were sold short at the 15 Oct 2026 settlement, 16.8% of the 6.7M shares outstanding; covering them would take 7.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $72.81 was 17.9% below its 50-day average ($88.66) and 5.7% below its 200-day average ($77.23). It has closed below the 200-day for 17 sessions, since 13 Oct 2026. The 50-day average crossed above the 200-day on 10 Jul 2026, 82 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $72.81 on 4 Nov 2026: 41.7% below the 52-week high of $124.82 (6 Aug 2026) and 45.4% above the low of $50.07 (29 Apr 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
October 24, 2024
+605.40%February 22, 2024
+96.49%February 20, 2024
+95.27%